Plasma homocysteine concentration related to diet, endothelial function and mononuclear cell gene expression among male hyperlipidaemic smokers

European Journal of Clinical Investigation

Volumn 29, Issue 2, 1999, Pages 100-108

  Brude, I R ^a   Finstad, H S ^a   Seljeflot, I ^b   Drevon, C A ^a   Solvoll, K ^a   Sandstad, B ^a   Hjermann, I ^b   Arnesen, H ^b   Nenseter, M S ^a,c  

^a UNIVERSITY OF OSLO   (Norway)

^b ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Adhesion molecules; Antioxidants; Cysteine; Cysteinylglycine; Omega 3 fatty acids; Transcription factors

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; BETA CAROTENE; CYANOCOBALAMIN; CYSTEINYLGLYCINE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FOLIC ACID; GLUTATHIONE PEROXIDASE; GLYCINE DERIVATIVE; HOMOCYSTEINE; MESSENGER RNA; OMEGA 3 FATTY ACID; PADGEM PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PROCOAGULANT; PROTEOGLYCAN; SERGLYCIN; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VON WILLEBRAND FACTOR;

ADULT; ARTICLE; ATHEROGENESIS; BLOOD LEVEL; CARDIOVASCULAR DISEASE; CELL FUNCTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET; DIETARY INTAKE; DOUBLE BLIND PROCEDURE; ENDOTHELIUM CELL; ENZYME ACTIVITY; FOLIC ACID BLOOD LEVEL; GENE EXPRESSION; HUMAN; HYPERLIPIDEMIA; MALE; MONONUCLEAR CELL; ONCOGENE C MYC; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SMOKING; THROMBOGENESIS; VEGETABLE; VITAMIN BLOOD LEVEL;

ADULT; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; DIET; DOUBLE-BLIND METHOD; FATTY ACIDS, OMEGA-3; GLUTATHIONE PEROXIDASE; HOMOCYSTEINE; HUMANS; HYPERLIPIDEMIAS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; RISK FACTORS; RNA, MESSENGER; SMOKING; VITAMINS;

EID: 0033035462     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.1999.00419.x     Document Type: Article

References (56)

1. 1 Harker LA, Slichter SJ, Scott CR, Ross R. Homocystinemia. Vascular injury and arterial thrombosis. N Engl J Med 1974; 291: 537-43.
2. 2 Clarke R, Daly L, Robinson K, et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 1991; 324: 1149-55.
3. 3 Ueland PM, Refsum H, Brattström L. Plasma homocysteine and cardiovascular disease. In: Francis RBJ, editor. Atherosclerotic cardiovascular disease, hemostasis, and endothelial function. New York: Marcel Dekker; 1992. p.182-222.
4. 4 Boushey CJ, Beresford SA, Omenn GS, Motulsky AGA. quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995; 274: 1049-57.
5. 5 Mayer EL, Jacobsen DW, Robinson K. Homocysteine and coronary atherosclerosis. J Am Coll Cardiol 1996; 27: 517-27.
6. 6 Bellamy MF, McDowell IFW. Putative mechanisms for vascular damage by homocysteine. J Inher Metab Dis 1997; 20: 307-15.
7. 7 D'Angelo A, Selhub J. Homocysteine and thrombotic disease. Blood 1997; 90: 1-11.
8. 8 Selhub JD, D'Angelo A. Hyperhomocysteinemia and thrombosis: acquired conditions. Thromb Haemostas 1997; 78: 527-31.
9. 9 Wang H, Yoshizumi M, Lai K, et al. Inhibition of growth and p21ras methylation in vascular endothelial cells by homocysteine but not cysteine. J Biol Chem 1997; 272: 25380-5.
10. 10 Upchurch GRJ, Welch GN, Freedman JE, Loscalzo J. Homocysteine attenuates endothelial glutathione peroxidase and thereby potentiates peroxide-mediated cell injury. Circulation 1995; 92: I-228.
11. 11 Upchurch GR Jr, Welch GN, Fabian AJ, et al. Homocyst(e)ine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase. J Biol Chem 1997; 272: 17012-7.
12. 12 Kokame K, Kato H, Miyata T. Homocysteine-respondent genes in vascular endothelial cells identified by differential display analysis. GRP78/BiP and novel genes. J Biol Chem 1996; 271: 29659-65.
13. 13 Lentz SR, Sadler JE. Homocysteine inhibits von Willebrand factor processing and secretion by preventing transport from the endoplasmic reticulum. Blood 1993; 81: 683-9.
14. 14 Tsai JC, Perrella MA, Yoshizumi M, et al. Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. Proc Natl Acad Sci USA 1994; 91: 6369-73.
15. 15 Tsai JC, Wang H, Perrella MA, et al. Induction of cyclin A gene expression by homocysteine in vascular smooth muscle cells. J Clin Invest 1996; 97: 146-53.
16. 16 Lubec B, Arbeiter K, Hoeger H, Lubec G. Increased cyclin dependent kinase in aortic tissue of rats fed homocysteine. Thromb Haemost 1996; 75: 542-5.
17. 17 Lubec B, Labudova O, Hoeger H, et al. Homocysteine increases cyclin-dependent kinase in aortic rat tissue. Circulation 1996; 94: 2620-5.
18. 18 Dalton ML, Gadson PF Jr, Wrenn RW, Rosenquist TH. Homocysteine signal cascade: production of phospholipids, activation of protein kinase C, and the induction of c-fos and c-myb in smooth muscle cells. FASEB J 1997; 11: 703-11.
19. 19 Parthasarathy S. Oxidation of low-density lipoprotein by thiol compounds leads to its recognition by the acetyl LDL receptor. Biochim Biophys Acta 1987; 917: 337-40.
20. 20 Heinecke JW, Kawamura M, Suzuki L, Chait A. Oxidation of low density lipoprotein by thiols: superoxide-dependent and -independent mechanisms. J Lipid Res 1993; 34: 2051-61.
21. 21 Hirano K, Ogihara T, Miki M, et al. Homocysteine induces iron-catalyzed lipid peroxidation of low-density lipoprotein that is prevented by alpha-tocopherol. Free Radic Res 1994; 21: 267-76.
22. 22 Halvorsen B, Brude I, Drevon CA, et al. Effect of homocysteine on copper ion-catalyzed, azo compound-initiated, and mononuclear cell-mediated oxidative modification of low density lipoprotein. J Lipid Res 1996; 37: 1591-600.
23. 23 Wall RT, Harlan JM, Harker LA, Striker GE. Homocysteine-induced endothelial cell injury in vitro: a model for the study of vascular injury. Thromb Res 1980; 18: 113-21.
24. 24 Jones BG, Rose FA, Tudball N. Lipid peroxidation and homocysteine induced toxicity. Atherosclerosis 1994; 105: 165-70.
25. 25 Dudman NP, Hicks C, Wang J, Wilcken DE. Human arterial endothelial cell detachment in vitro: its promotion by homocysteine and cysteine. Atherosclerosis 1991; 91: 77-83.
26. 26 Refsum H, Ueland PM, Nygard O, Vollset SE. Homocysteine and cardiovascular disease. Annu Rev Med 1998; 49: 31-62.
27. 27 Uhlin-Hansen L, Wik T, Kjellen L, Berg E, Forsdahl F, Kolset SO. Proteoglycan metabolism in normal and inflammatory human macrophages. Blood 1993; 82: 2880-9.
28. 28 Brude IR, Drevon CA, Hjermann I, et al. Peroxidation of LDL from combined-hyperlipidemic male smokers supplied with w-3 fatty acids and antioxidants. Arteriosecler Thromb Vasc Biol 1997; 17: 2576-88.
29. 29 Andersen LF, Solvoll K, Drevon CA. Very-long-chain n-3 fatty acids as biomarkers for intake of fish and n-3 fatty acid concentrates. Am J Clin Nutr 1996; 64: 305-11.
30. 30 Refsum H, Ueland PM, Svardal AM. Fully automated fluorescence assay for determining total homocysteine in plasma. Clin Chem 1989; 35: 1921-7.
31. 31 Fiskerstrand T, Refsum H, Kvalheim G, Ueland PM. Homocysteine and other thiols in plasma and urine: automated determination and sample stability. Clin Chem 1993; 39: 263-71.
32. 32 Nygard O, Vollset SE, Refsum H, et al. Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine Study JAMA 1995; 274: 1526-33.
33. 33 Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162: 156-9.
34. 34 Finstad HS, Myhrstad MCW, Heimli HL, et al. Multiplication and death-type of leukemia cell lines exposed to very long-chain polyunsaturated fatty acids. Leukemia 1998; 12: 921-9.
35. 35 Paglia DE, Valentine WN. Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med 1967; 70: 158-69.
36. 36 Tribble DL, Giuliano LJ, Fortmann SP. Reduced plasma ascorbic acid concentrations in nonsmokers regularly exposed to environmental tobacco smoke. Am J Clin Nutr 1993; 58: 886-90.
37. 37 Bostom AG, Yanek L, Hume AL, et al. High dose ascorbate supplementation fails to affect plasma homocyst(e)ine levels in patients with coronary heart disease. Atherosclerosis 1994; 111: 267-70.
38. 38 Haglund O, Hamfelt A, Hambraeus L, Saldeen T. Effects of fish oil supplemented with pyridoxine and folic acid on homocysteine, atherogenic index, fibrinogen and plasminogen activator inhibitor-1 in man. Nutr Res 1993; 13: 1351-65.
39. 39 Olszewski AJ, McCully KS. Fish oil decreases serum homocysteine in hyperlipemic men. Coron Artery Dis 1993; 4: 53-60.
40. 40 Johansson L, Solvoll K, Bjørneboe G-EA, Drevon CA. Intake of very-long-chain n-3 fatty acids in relation to lifestyle. Eur J Clin Nutr 1998; 52: 716-21.
41. 41 Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997; 337: 230-6.
42. 42 Lentz SR, Sadler JE. Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine. J Clin Invest 1991; 88: 1906-14.
43. 43 Van den Berg M, Boers GH, Franken DG, et al. Hyperhomocysteinaemia and endothelial dysfunction in young patients with peripheral arterial occlusive disease. Eur J Clin Invest 1995; 25: 176-81.
44. 44 Evans RM. The steroid and thyroid hormone receptor superfamily. Science 1988; 240: 889-95.
45. 45 Forman BM, Chen J, Evans RM. The peroxisome proliferator-activated receptors: ligands and activators. Ann N Y Acad Sci 1996; 804: 266-75.
46. 46 Schoonjans K, Staels B, Auwerx J. The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation. Biochim Biophys Acta 1996; 1302: 93-109.
47. 47 Harrigan MT, Baughman G, Campbell NF, Bourgeois S. Isolation and characterization of glucocorticoid-and cyclic AMP-induced genes in T lymphocytes. Mol Cell Biol 1989; 9: 3438-46.
48. 48 Evan G, Harrington E, Fanidi A, Land H, Amati B, Bennett M. Integrated control of cell proliferation and cell death by the c-myc oncogene. Philos Trans R Soc Lond B Biol Sci 1994; 345: 269-75.
49. 49 Duyao MP, Buckler AJ, Sonenshein GE. Interaction of an NF-kappa B-like factor with a site upstream of the c-myc promoter. Proc Natl Acad Sei USA 1990; 87: 4727-31.
50. 50 Welch GN, Upchurch GR Jr, Farivar RS, et al. Homocysteine-induced nitric oxide production in vascular smooth-muscle cells by NF-kappa B-dependent transcriptional activation of Nos2. Proc Assoc Am Physicians 1998; 110: 22-31.
51. 51 Suttorp N, Toepfer W, Roka L. Antioxidant defense mechanisms of endothelial cells: glutathione redox cycle vs. catalase. Am J Physiol 1986; 251: C671-80.
52. 52 Jongkind JF, Verkerk A, Baggen RG. Glutathione metabolism of human vascular endothelial cells under peroxidative stress. Free Radic Biol Med 1989; 7: 507-12.
53. 53 Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989; 320: 915-24.
54. 54 Holvoet P, Collen D. Oxidized lipoproteins in atherosclerosis and thrombosis. FASEB J 1994; 8: 1279-84.
55. 55 Blom HJ, Kleinveld HA, Boers GH, et al. Lipid peroxidation and susceptibility of low-density lipoprotein to in vitro oxidation in hyperhomocysteinaemia. Eur J Clin Invest 1995; 25: 149-54.
56. 56 Cordoba-Porras A, Sanchez-Quesada JL, Gonzalez-Sastre F, Ordonez-Llanos J, Blanco-Vaca F. Susceptibility of plasma low-and high-density lipoproteins to oxidation in patients with severe hyperhomocysteinemia. J Mol Med 1996; 74: 771-6.